SOTIO Overviews DUET-01 Phase 1/2 Study at ASCO Meeting

PRAGUE, BASEL, and BOSTON—SOTIO Biotech, a clinical-stage immuno-oncology enterprise under PPF Group, is set to unveil new insights into its DUET-01 Phase 1/2 study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024. This study represents the first human trial assessing BOXR1030, a CAR T-cell therapy enhanced for better metabolic performance, aimed at treating solid tumors.

The ongoing DUET-01 clinical trial (NCT05120271) is actively enrolling and dosing patients across three prominent U.S. cancer treatment facilities, with plans to include additional sites in the U.K. shortly.

Dr. Ecaterina Dumbrava, Assistant Professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and principal investigator for the DUET-01 trial, emphasized the transformative potential of CAR T-cell therapies for blood cancers. However, she noted that their efficacy in solid tumors has been limited due to the complexities of the tumor microenvironment. Dr. Dumbrava highlighted that BOXR1030, which targets GPC3, has demonstrated promising preclinical outcomes, particularly in resisting conditions similar to those found in tumor microenvironments and boosting T cell proliferation compared to conventional CAR T cells. GPC3 is a validated target with high prevalence in several challenging solid tumor types, and the preliminary data indicates substantial promise for BOXR1030 in clinical applications.

The DUET-01 trial is an open-label, multicenter, dose-escalation study designed to identify the optimal Phase 2 dosing for BOXR1030 in patients with advanced GPC3-positive solid tumors. The study aims to recruit up to 98 participants suffering from advanced, inoperable hepatocellular carcinoma, squamous cell lung cancer, myxoid/round cell liposarcoma, and Merkel cell carcinoma.

SOTIO Biotech will make presentation materials available on June 1, following the session's conclusion.

About SOTIO Biotech

SOTIO Biotech is committed to revolutionizing cancer immunotherapies by transforming innovative scientific research into tangible patient benefits. The company’s pipeline includes SOT102, a Claudin-18.2-targeting antibody-drug conjugate now in clinical trials since 2022; BOXR1030, a metabolically enhanced CAR-T cell therapy targeting GPC3-expressing tumors; and other promising candidates like SOT201, a next-generation PD-1-inhibiting immunocytokine nearing clinical stages. SOTIO Biotech is a subsidiary of PPF Group and operates under the registered trademark of SOTIO Biotech a.s.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!